377 related articles for article (PubMed ID: 18829517)
1. Letrozole is superior to anastrozole in suppressing breast cancer tissue and plasma estrogen levels.
Geisler J; Helle H; Ekse D; Duong NK; Evans DB; Nordbø Y; Aas T; Lønning PE
Clin Cancer Res; 2008 Oct; 14(19):6330-5. PubMed ID: 18829517
[TBL] [Abstract][Full Text] [Related]
2. Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer.
Dixon JM; Renshaw L; Young O; Murray J; Macaskill EJ; McHugh M; Folkerd E; Cameron DA; A'Hern RP; Dowsett M
J Clin Oncol; 2008 Apr; 26(10):1671-6. PubMed ID: 18375896
[TBL] [Abstract][Full Text] [Related]
3. Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer.
Cohen MH; Johnson JR; Li N; Chen G; Pazdur R
Clin Cancer Res; 2002 Mar; 8(3):665-9. PubMed ID: 11895893
[TBL] [Abstract][Full Text] [Related]
4. Anastrozole ('Arimidex') blocks oestrogen synthesis both peripherally and within the breast in postmenopausal women with large operable breast cancer.
Miller WR; Stuart M; Sahmoud T; Dixon JM
Br J Cancer; 2002 Oct; 87(9):950-5. PubMed ID: 12434282
[TBL] [Abstract][Full Text] [Related]
5. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study.
Geisler J; Haynes B; Anker G; Dowsett M; Lønning PE
J Clin Oncol; 2002 Feb; 20(3):751-7. PubMed ID: 11821457
[TBL] [Abstract][Full Text] [Related]
6. Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer.
Folkerd EJ; Dixon JM; Renshaw L; A'Hern RP; Dowsett M
J Clin Oncol; 2012 Aug; 30(24):2977-80. PubMed ID: 22802308
[TBL] [Abstract][Full Text] [Related]
7. Influence of neoadjuvant anastrozole (Arimidex) on intratumoral estrogen levels and proliferation markers in patients with locally advanced breast cancer.
Geisler J; Detre S; Berntsen H; Ottestad L; Lindtjørn B; Dowsett M; Einstein Lønning P
Clin Cancer Res; 2001 May; 7(5):1230-6. PubMed ID: 11350888
[TBL] [Abstract][Full Text] [Related]
8. Anastrozole and letrozole: an investigation and comparison of quality of life and tolerability.
Dixon JM; Renshaw L; Langridge C; Young OE; McHugh M; Williams L; Murray J; Macaskill EJ; McCaig F; Dixon OM; Fallowfield LJ
Breast Cancer Res Treat; 2011 Feb; 125(3):741-9. PubMed ID: 20821047
[TBL] [Abstract][Full Text] [Related]
9. In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer.
Dowsett M; Jones A; Johnston SR; Jacobs S; Trunet P; Smith IE
Clin Cancer Res; 1995 Dec; 1(12):1511-5. PubMed ID: 9815951
[TBL] [Abstract][Full Text] [Related]
10. An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
Henriksen KL; Rasmussen BB; Lykkesfeldt AE; Møller S; Ejlertsen B; Mouridsen HT
Acta Oncol; 2009; 48(4):522-31. PubMed ID: 19173092
[TBL] [Abstract][Full Text] [Related]
11. Plasma estrogen suppression with aromatase inhibitors evaluated by a novel, sensitive assay for estrone sulphate.
Lønning PE; Geisler J; Johannessen DC; Ekse D
J Steroid Biochem Mol Biol; 1997 Apr; 61(3-6):255-60. PubMed ID: 9365198
[TBL] [Abstract][Full Text] [Related]
12. Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole.
Ellis MJ; Tao Y; Young O; White S; Proia AD; Murray J; Renshaw L; Faratian D; Thomas J; Dowsett M; Krause A; Evans DB; Miller WR; Dixon JM
J Clin Oncol; 2006 Jul; 24(19):3019-25. PubMed ID: 16754938
[TBL] [Abstract][Full Text] [Related]
13. A novel HPLC-RIA method for the simultaneous detection of estrone, estradiol and estrone sulphate levels in breast cancer tissue.
Geisler J; Berntsen H; Lonning PE
J Steroid Biochem Mol Biol; 2000 Apr; 72(5):259-64. PubMed ID: 10822015
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of breast cancer tissue aromatase activity and estrogen concentrations by the third-generation aromatase inhibitor vorozole.
de Jong PC; van de Ven J; Nortier HW; Maitimu-Smeele I; Donker TH; Thijssen JH; Slee PH; Blankenstein RA
Cancer Res; 1997 Jun; 57(11):2109-11. PubMed ID: 9187104
[TBL] [Abstract][Full Text] [Related]
15. The effects of neoadjuvant anastrozole and tamoxifen on circulating vascular endothelial growth factor and soluble vascular endothelial growth factor receptor 1 in breast cancer.
Banerjee S; Pancholi S; A'hern R; Ghazoui Z; Smith IE; Dowsett M; Martin LA
Clin Cancer Res; 2008 May; 14(9):2656-63. PubMed ID: 18451229
[TBL] [Abstract][Full Text] [Related]
16. Serum soluble epidermal growth factor receptor concentrations decrease in postmenopausal metastatic breast cancer patients treated with letrozole.
Lafky JM; Baron AT; Cora EM; Hillman DW; Suman VJ; Perez EA; Ingle JN; Maihle NJ
Cancer Res; 2005 Apr; 65(8):3059-62. PubMed ID: 15833834
[TBL] [Abstract][Full Text] [Related]
17. Histopathology of breast carcinoma following neoadjuvant systemic therapy: a common association between letrozole therapy and central scarring.
Thomas JS; Julian HS; Green RV; Cameron DA; Dixon MJ
Histopathology; 2007 Aug; 51(2):219-26. PubMed ID: 17650216
[TBL] [Abstract][Full Text] [Related]
18. Effects of the antiestrogen tamoxifen and the aromatase inhibitor letrozole on serum hormones and bone characteristics in a preclinical tumor model for breast cancer.
Núñez NP; Jelovac D; Macedo L; Berrigan D; Perkins SN; Hursting SD; Barrett JC; Brodie A
Clin Cancer Res; 2004 Aug; 10(16):5375-80. PubMed ID: 15328175
[TBL] [Abstract][Full Text] [Related]
19. Superiority of gas chromatography/tandem mass spectrometry assay (GC/MS/MS) for estradiol for monitoring of aromatase inhibitor therapy.
Santen RJ; Demers L; Ohorodnik S; Settlage J; Langecker P; Blanchett D; Goss PE; Wang S
Steroids; 2007 Jul; 72(8):666-71. PubMed ID: 17588628
[TBL] [Abstract][Full Text] [Related]
20. Serum TIMP-1 and response to the aromatase inhibitor letrozole versus tamoxifen in metastatic breast cancer.
Lipton A; Leitzel K; Chaudri-Ross HA; Evans DB; Ali SM; Demers L; Hamer P; Brown-Shimer S; Pierce K; Gaur V; Carney W
J Clin Oncol; 2008 Jun; 26(16):2653-8. PubMed ID: 18443351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
